Day: April 24, 2024

Paris, 24 April 2024 Caffil has amended the Final Terms dated 4 April 2024 relating to the issue of €50,000,000 3.60 per cent. obligations foncières due 8 April 2054 (ISIN Code: FR001400PAP5) (the “Obligations Foncières“) under its €75,000,000,000 EMTN Programme (the “Amended and Restated Final Terms“). The amendment provides for the admission to trading of the Obligations Foncières on the regulated market of the Luxembourg Stock Exchange as from 24 April 2024 and the additional conditions of publication of the Amended and Restated Final Terms. The Amended and Restated Final Terms relating to the issue of the Obligations Foncières will be available on the website of the AMF (www.amf-france.org), the Luxembourg Stock Exchange (www.bourse.lu) and the issuer (www.caissefrancaisedefinancementlocal.fr).Attachment...

Reference is made to the announcement of Fly Play hf. (“PLAY” or the “Company”) on April 11, 2024, regarding the results of a funding round. In a meeting held today, the Company’s Board of Directors decided to exercise the authority granted by the AGM to increase the Company’s share capital by issuing new shares by up to 1,200,000,000 shares in nominal value. As previously announced, the total amount of the authorization will not be used. The Company’s Board of Directors decided at a meeting today to increase the Company’s share capital by issuing 1,023,155,559 new shares, each with a nominal value of 1 ISK. The new shares will be delivered to investors on April 29, 2024, and admission to trading of the new shares on Nasdaq First North Growth Market Iceland is scheduled to commence on the same day under the symbol PLAY (ISIN:...

  NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II trial evaluating the company’s therapeutic cancer vaccine candidate UV1 in combination with the checkpoint inhibitors ipilimumab and nivolumab as first-line treatment in unresectable or metastatic malignant melanoma. The trial was conducted at 39 hospitals across the U.S., U.K., Belgium, and Norway, and 156 patients were enrolled between June 2020 and July 2022....

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors. “We are pleased to present our initial clinical findings for CLN-619 plus pembrolizumab in patients with solid tumors at ASCO 2024, along with updated results from our monotherapy...

District Photo, a Canon Solutions America ProStream customer, hosts students from the programDistrict PhotoCanon Solutions America customer District Photo has assisted the University Inkjet Program’s educational mission by hosting field trips.MELVILLE, N.Y., April 24, 2024 (GLOBE NEWSWIRE) — Providing real-world experience to complement classroom instruction can bring classroom learning to life and give students insight into what a career in the printing industry would be like. Canon Solutions America, a wholly owned subsidiary of Canon U.S.A., Inc., continues to support programs with this sentiment in mind, including the fifth year of the University Inkjet Program that works to help develop the next generation of printing industry professionals. The University Inkjet Program, launched in 2019, offers students practical...

Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 24 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, will present Phase 1 expansion data for brenetafusp (IMC-F106C), the first off-the-shelf ImmTAC therapy targeting PRAME, in patients with late-line cutaneous melanoma, all previously treated with anti-PD1 and the vast majority having received...